RCMI Coordinating Center (RCMI CC) Header Logo

Connection

George Perry to Drug Evaluation, Preclinical

This is a "connection" page, showing publications George Perry has written about Drug Evaluation, Preclinical.
Connection Strength

0.187
  1. Singh SK, Srivastav S, Yadav AK, Srikrishna S, Perry G. Overview of Alzheimer's Disease and Some Therapeutic Approaches Targeting A? by Using Several Synthetic and Herbal Compounds. Oxid Med Cell Longev. 2016; 2016:7361613.
    View in: PubMed
    Score: 0.131
  2. Doens D, Valiente PA, Mfuh AM, X T Vo A, Tristan A, Carre?o L, Quijada M, Nguyen VT, Perry G, Larionov OV, Lleonart R, Fern?ndez PL. Identification of Inhibitors of CD36-Amyloid Beta Binding as Potential Agents for Alzheimer's Disease. ACS Chem Neurosci. 2017 06 21; 8(6):1232-1241.
    View in: PubMed
    Score: 0.035
  3. Tabaton M, Perry G, Zhu X, Lee HG, Casadesus G, Smith MA. Memantine: "hypothesis testing" not "disease modifying" in Alzheimer's disease. Am J Pathol. 2010 Feb; 176(2):540-1.
    View in: PubMed
    Score: 0.021
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support